Companies › FutureGen Biopharmaceutical (Beijing)
1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| M108 monoclonal antibody anti-CLDN18.2 monoclonal antibody | CLDN18 | Phase 3 | Locally Advanced Unresectable or Metastatic Gastric Cancer | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06177041 | M108 monoclonal antibody | Phase 3 | Locally Advanced Unresectable or Metastatic Gastric Cancer | Oncology | Jan 2027 |
Suzhou Immunofoco Biotechnology LaNova Medicines Zhejiang Alentis Therapeutics NingBo Junyan Hongshi Biosciences Biokin (Shanghai) Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.